Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients
Tao Zhang1, Dan Sun1, Zuocheng Shu1
1Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Insights
Teicoplanin dosing in children needs adjustment for optimal effectiveness. Standard regimens may not achieve target concentrations, especially for severe infections, necessitating higher doses for better outcomes.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Infectious Diseases
Background:
- Teicoplanin pharmacokinetics (PK) exhibit significant differences between pediatric and adult populations.
- Optimizing teicoplanin dosage in children is crucial for effective treatment of bacterial infections.
- Existing standard dosing regimens may be inadequate for achieving therapeutic targets in pediatric patients.
Purpose of the Study:
- To determine teicoplanin pharmacokinetics in an Asian pediatric population.
- To optimize teicoplanin dosage regimens for pediatric patients.
- To evaluate standard and alternative dosing strategies using population PK modeling and simulations.
Main Methods:
- Retrospective analysis of PK data from hospitalized pediatric patients.
- Development of a population PK model utilizing sparse data.
- Monte Carlo simulations to assess various teicoplanin dosage regimens against defined therapeutic targets (Cmin and AUC24/MIC).
Main Results:
- Estimated teicoplanin clearance was 0.694 L/h and volume of distribution was 1.39 L.
- Standard loading dose was adequate for moderate infections, but 13 mg/kg was needed for severe infections.
- Standard maintenance doses failed to achieve target Cmin for both moderate and severe infections; higher doses (12-16 mg/kg/day) were required. Standard maintenance dose achieved AUC24/MIC targets for moderate infections, but 12 mg/kg/day was needed for severe infections.
Conclusions:
- Optimal teicoplanin doses based on Cmin targets were higher than those based on PK/PD targets.
- Standard loading doses were adequate for moderate infections, but higher-than-standard maintenance doses are required for moderate and severe infections to achieve both Cmin and PK/PD targets.
- Further clinical studies with comprehensive sampling are necessary to validate these findings.
Abstract:
Objectives: The pharmacokinetics (PK) of teicoplanin differs in children compared with adults. Our aim was to determine the PK of teicoplanin in an Asian pediatric population and to optimize dosage regimens. Methods: This was a retrospective PK study and all the data were collected from hospitalized children. We developed a population PK model using sparse data, and Monte Carlo simulation was used to assess the ability of standard teicoplanin regimen and other different dosage regimens. The optimal dosing regimens were defined as achieving the target trough concentration (C min) of 10 mg/L and pharmacokinetic/pharmacodynamic (PK/PD, [AUC24/MIC]) of 125 for moderate infection. For severe infection, the optimal dosing regimens were defined as achieving the target 15 mg/L and AUC24/MIC of 345. Results: 159 children were included and 1.5 samples/children on average were provided. Estimated clearance of teicoplanin was 0.694 L/h (0.784/L/h/70 kg) and volume of distribution was 1.39 L. Teicoplanin standard loading dose was adequate for moderate infection, while 13 mg/kg was needed for severer infection. With standard maintenance doses, both patients with moderate and severe infection failed to achieve the target C min. 12 and 16 mg/kg/day were required to achieve a C min ≥ 10 and 15 mg/L, respectively. However, standard maintenance dose was adequate to achieve AUC24/MIC ≥ 125 for moderate infection, and 12 mg/kg/day was needed to achieve AUC24/MIC ≥ 345 for severe infection. Lower weight and serum creatinine were associated with higher dose. Conclusion: Optimal doses based on the target C min were higher than that based on the PK/PD target. To achieve the C min and PK/PD targets simultaneously, a standard loading dose was adequate for moderate infection based on simulation, while dosing higher than standard doses were required in other situation. Further clinical studies with rich sampling from children is required to confirm our findings.
More Related Videos
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:29Drug Dosing: Infants and Children
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption